UC San Francisco
San Francisco, CA
Adam Boxer, MD, PhD
Site PI
Adam L. Boxer, MD, PhD, is Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF). He directs UCSF’s Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. Dr. Boxer’s research is focused on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43. Dr. Boxer received his medical and doctorate degrees as part of the NIH-funded Medical Scientist Training Program at New York University Medical Center. He completed an internship in Internal Medicine at California Pacific Medical Center, a residency in Neurology at Stanford University Medical Center, followed by a fellowship in behavioral neurology at UCSF. He is the principal investigator (PI) of the Advancing Research and Treatment for FTLD (ARTFL) Rare Disease Clinical Research Consortium and he also leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI). He has been the PI for a variety of clinical trials in FTLD spectrum disorders and has also led a variety of clinical trials in FTD and PSP. He is lead principal investigator for an international Phase 2 clinical trial of the tau monoclonal antibody, BIIB092, for PSP. He also leads the FTD Treatment Study Group (FTSG).
Julio Rojas, MD, PhD
Site Co-PI
Julio C. Rojas is the John F. Douglas Alzheimer’s Foundation Associate Professor of Neurology at the Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco. He has a medical degree from the Tech of Monterrey School of Medicine in Mexico and a doctorate in Neuroscience from the University of Texas at Austin. He completed Neurology residency at UT Southwestern Medical Center in Dallas and a fellowship in behavioral neurology at UCSF. Dr. Rojas is experienced in dementia care and research. He is the site PI for ongoing industry-sponsored phase 3 trials of anti-amyloid therapies in Alzheimer’s disease and pursues NIA-funded research on fluid biomarker discovery and development for Alzheimer’s disease and frontotemporal dementia.
